| Name
|
[Arg8] Vasopressin /AVP
|
| Code
|
[113-79-1]
|
| The alias
|
[Arg8] Vasopressin /AVP
|
| Sequence (single letter abbreviation)
|
CYFQNCPRG-NH2?(C1&C6 bridge)
|
| Sequence (three-letter abbreviation)
|
H-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2?(trifluoroacetate salt)(Cys1 and 6 bridge)
|
| A basic description
|
Lyophilized synthetic solid whose analog is less potent than that [Arg8]-Vasopressin. This peptide, however, has reduced vasopressor and antidiuretic activity when compared to AVP.
|
| solubility
|
|
| The molecular weight
|
1084.3
|
| Chemical formula
|
C46H65N15O12S2
|
| The purity
|
80%，90%，95%，98%，99%
|
| Weight
|
1mg,5mg,10mg,50mg,100mg,1g
|
| Storage conditions
|
Store at -20°C. Keep tightly closed. Store in a cool dry place.
|
| Annotation
|
|
| Documents
|
|
| Figures
|
|
| Reference
|
A.Lagumdzija et al., Regul. Pept., 121, 41 (2004)
Y.Isobe et al., Brain Res., 918, 67 (2001)
H.Hashimoto et al., Neuropeptides, 12, 199 (1988)
J. Bell et al., Intl. J. Immunopharmacol., 14, 92 (1992)
|
| The C-terminal
|
|
| The N-terminal
|
|
| Chemical bridge
|
(Cys1 and 6 bridge)
|